259 related articles for article (PubMed ID: 38637634)
21. Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition.
Vaclova T; Chakraborty A; Sherwood J; Ross S; Carroll D; Barrett JC; Downward J; de Bruin EC
Sci Rep; 2022 Feb; 12(1):2699. PubMed ID: 35177674
[TBL] [Abstract][Full Text] [Related]
22. KRAS Inhibitors- yes but what next? Direct targeting of KRAS- vaccines, adoptive T cell therapy and beyond.
Nagasaka M; Potugari B; Nguyen A; Sukari A; Azmi AS; Ou SI
Cancer Treat Rev; 2021 Dec; 101():102309. PubMed ID: 34715449
[TBL] [Abstract][Full Text] [Related]
23. Reflections on drug resistance to KRAS
Han Z; Zhou D; Wang J; Jiang B; Liu X
Biochim Biophys Acta Rev Cancer; 2022 Jan; 1877(1):188677. PubMed ID: 35033622
[TBL] [Abstract][Full Text] [Related]
24. HER2 mediates clinical resistance to the KRAS
Ho CSL; Tüns AI; Schildhaus HU; Wiesweg M; Grüner BM; Hegedus B; Schuler M; Schramm A; Oeck S
Eur J Cancer; 2021 Dec; 159():16-23. PubMed ID: 34715459
[TBL] [Abstract][Full Text] [Related]
25. BCL-X
Khan S; Wiegand J; Zhang P; Hu W; Thummuri D; Budamagunta V; Hua N; Jin L; Allegra CJ; Kopetz SE; Zajac-Kaye M; Kaye FJ; Zheng G; Zhou D
J Hematol Oncol; 2022 Mar; 15(1):23. PubMed ID: 35260176
[TBL] [Abstract][Full Text] [Related]
26. KRAS-targeted therapy in the treatment of non-small cell lung cancer.
Yun J; Nakagawa R; Tham K
J Oncol Pharm Pract; 2023 Mar; 29(2):422-430. PubMed ID: 35938195
[TBL] [Abstract][Full Text] [Related]
27. Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges.
Tang D; Kroemer G; Kang R
Mol Cancer; 2021 Oct; 20(1):128. PubMed ID: 34607583
[TBL] [Abstract][Full Text] [Related]
28. Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients.
Kim D; Xue JY; Lito P
Cell; 2020 Nov; 183(4):850-859. PubMed ID: 33065029
[TBL] [Abstract][Full Text] [Related]
29. Management of
Malhotra J; Nguyen D; Tan T; Semeniuk Iii GB
Clin Adv Hematol Oncol; 2024 Mar; 22(2):67-75. PubMed ID: 38446474
[TBL] [Abstract][Full Text] [Related]
30. On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma.
Lindsay CR; Garassino MC; Nadal E; Öhrling K; Scheffler M; Mazières J
Lung Cancer; 2021 Oct; 160():152-165. PubMed ID: 34417059
[TBL] [Abstract][Full Text] [Related]
31. Targeting KRAS Diversity: Covalent Modulation of G12X and Beyond in Cancer Therapy.
Kirschner T; Müller MP; Rauh D
J Med Chem; 2024 Apr; 67(8):6044-6051. PubMed ID: 38621359
[TBL] [Abstract][Full Text] [Related]
32. Multiple medicinal chemistry strategies of targeting KRAS: State-of-the art and future directions.
Shang Y; Fu S; Hao Q; Ying H; Wang J; Shen T
Bioorg Chem; 2024 Mar; 144():107092. PubMed ID: 38271825
[TBL] [Abstract][Full Text] [Related]
33. The promise and peril of KRAS G12C inhibitors.
Moore AR; Malek S
Cancer Cell; 2021 Aug; 39(8):1059-1061. PubMed ID: 34375610
[TBL] [Abstract][Full Text] [Related]
34. Sotorasib: a treatment for non-small cell lung cancer with the KRAS G12C mutation.
Zheng X; Luo J; Liu W; Ashby CR; Chen ZS; Lin L
Drugs Today (Barc); 2022 Apr; 58(4):175-185. PubMed ID: 35412531
[TBL] [Abstract][Full Text] [Related]
35. [Current status and outlook of medical treatment for
Xu W; Zhuo XL; Liu L; Zhao J; Lin XY; Fu GB
Zhonghua Zhong Liu Za Zhi; 2023 Feb; 45(2):111-116. PubMed ID: 36781231
[TBL] [Abstract][Full Text] [Related]
36. Targeting
Burns TF; Borghaei H; Ramalingam SS; Mok TS; Peters S
J Clin Oncol; 2020 Dec; 38(35):4208-4218. PubMed ID: 33104438
[No Abstract] [Full Text] [Related]
37. Targeting KRAS in Colorectal Cancer.
Wang C; Fakih M
Curr Oncol Rep; 2021 Feb; 23(3):28. PubMed ID: 33582927
[TBL] [Abstract][Full Text] [Related]
38. KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?
Nagasaka M; Li Y; Sukari A; Ou SI; Al-Hallak MN; Azmi AS
Cancer Treat Rev; 2020 Mar; 84():101974. PubMed ID: 32014824
[TBL] [Abstract][Full Text] [Related]
39. Adagrasib in Non-Small-Cell Lung Cancer Harboring a
Jänne PA; Riely GJ; Gadgeel SM; Heist RS; Ou SI; Pacheco JM; Johnson ML; Sabari JK; Leventakos K; Yau E; Bazhenova L; Negrao MV; Pennell NA; Zhang J; Anderes K; Der-Torossian H; Kheoh T; Velastegui K; Yan X; Christensen JG; Chao RC; Spira AI
N Engl J Med; 2022 Jul; 387(2):120-131. PubMed ID: 35658005
[TBL] [Abstract][Full Text] [Related]
40. Recent progress in targeting KRAS mutant cancers with covalent G12C-specific inhibitors.
Rathod LS; Dabhade PS; Mokale SN
Drug Discov Today; 2023 May; 28(5):103557. PubMed ID: 36934967
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]